![](/images/Email.png)
TargetE3 ubiquitin-protein ligase Mdm2(Homo sapiens (Human))
ASTEX THERAPEUTICS LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED
US Patent
ASTEX THERAPEUTICS LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED
US Patent
Affinity DataIC50: 1.90nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2(Homo sapiens (Human))
ASTEX THERAPEUTICS LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED
US Patent
ASTEX THERAPEUTICS LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED
US Patent
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
In DepthDetails
TargetE3 ubiquitin-protein ligase Mdm2(Homo sapiens (Human))
ASTEX THERAPEUTICS LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED
US Patent
ASTEX THERAPEUTICS LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED
US Patent
Affinity DataIC50: 1.90nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 ul per well of 1 μg ml−1 biotinylated IP3 pep...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2(Homo sapiens (Human))
ASTEX THERAPEUTICS LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED
US Patent
ASTEX THERAPEUTICS LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED
US Patent
Affinity DataIC50: 10nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 ul per well of 1 μg ml−1 biotinylated IP3 pep...More data for this Ligand-Target Pair
![](/img/powered_by_small.gif)